Vantictumab, CAS 1345009-45-1

Product Description: Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab is being studied against cancers such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma[1][2].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Diamond JR, et al. Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res Treat. 2020 Nov;184(1):53-62./[2]Davis SL, et al. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Invest New Drugs. 2020 Jun;38(3):821-830.

CAS Number: 1345009-45-1

Molecular Weight: N/A

Compound Purity: 99.40

Research Area: Cancer

Solubility: 10 mM in DMSO/H2O

Target: Wnt

• Artikelnummer: MEXHY-P9974-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P9974-1
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated